UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

LIMBACH HOLDINGS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

53263P105

(CUSIP Number)

Brian Pratt

5950 Berkshire Ln, Ste. 800

Dallas, Texas 75225

Tel: (214) 220-3423

With a Copy to:

Jeffrey P. Berg

Baker & Hostetler LLP

11601 Wilshire Boulevard, Suite 1400

Los Angeles, California 90025

Tel: (310) 442-8850

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

 

 


CUSIP No. 53263P105

 

  1    

  NAME OF REPORTING PERSONS

 

  Brian Pratt

  2    

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☒

 

  3    

  SEC USE ONLY

 

  4    

  SOURCE OF FUNDS

 

  PF

  5    

  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

 

  ☐

  6    

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  UNITED STATES OF AMERICA

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    7     

  SOLE VOTING POWER

 

  0

  8     

  SHARED VOTING POWER

 

  1,537,800 (1)

  9     

  SOLE DISPOSITIVE POWER

 

  0

  10     

  SHARED DISPOSITIVE POWER

 

  1,537,800 (1)

11    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,537,800 (1)

12    

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

  ☐

13    

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

  19.58% (2)

14    

  TYPE OF REPORTING PERSON

 

  IN

 

(1)

Represents those shares of common stock, par value $0.0001 per share (“Common Stock”), of Limbach Holdings, Inc., a Delaware corporation (the “Company”), jointly held as community property by Mr. Pratt and his spouse, Barbara Pratt, as of July 31, 2020. Mr. Pratt and Mrs. Pratt share voting and dispositive power with respect to such shares.

(2)

Based on 7,853,377 shares of Common Stock outstanding as of June 14, 2020, as reported in the Company’s Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on June 15, 2020.


CUSIP No. 53263P105

 

  1    

  NAME OF REPORTING PERSONS

 

  Barbara Pratt

  2    

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐        (b)  ☒

 

  3    

  SEC USE ONLY

 

  4    

  SOURCE OF FUNDS

 

  PF

  5    

  CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

 

  ☐

  6    

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  UNITED STATES OF AMERICA

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    7     

  SOLE VOTING POWER

 

  0

  8     

  SHARED VOTING POWER

 

  1,537,800 (1)

  9     

  SOLE DISPOSITIVE POWER

 

  0

  10     

  SHARED DISPOSITIVE POWER

 

  1,537,800 (1)

11    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,537,800 (1)

12    

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

 

  ☐

13    

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

  19.58% (2)

14    

  TYPE OF REPORTING PERSON

 

  IN

 

(1)

Represents those shares of Common Stock of the Company, jointly held as community property by Mrs. Pratt and her spouse, Brian Pratt, as of July 31, 2020. Mr. Pratt and Mrs. Pratt share voting and dispositive power with respect to such shares.

(2)

Based on 7,853,377 shares of Common Stock outstanding as of June 14, 2020, as reported in the Company’s Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on June 15, 2020.

 


AMENDMENT NO. 1 TO SCHEDULE 13D

This Amendment No. 1 (this “Amendment No. 1”) to the statement on Schedule 13D amends and supplements the statement on Schedule 13D filed by certain of the Reporting Persons on March 31, 2020 (the “Original 13D Filing,” and together with this Amendment No. 1, the “Schedule 13D”). Except as amended in this Amendment No. 1, the Original 13D Filing remains in full force and effect. Unless otherwise indicated, all capitalized terms used but not defined herein shall have the same meaning ascribed to them in the Original 13D Filing.

This Amendment No. 1 is being filed to make updates and amendments to the Schedule 13D as follows:

 

Item 1.

Security and Issuer.

There are no changes to the Item 1 information previously filed.

 

Item 2.

Identity and Background.

There are no changes to the Item 2 information previously filed.

 

Item 3.

Source and Amount of Funds or Other Consideration.

There are no changes to the Item 3 information previously filed.


Item 4.

Purpose of Transaction.

Item 4 is hereby amended and restated in its entirety below:

On July 31, 2020, the Reporting Persons and a third-party investment company (the “Investors”) presented a non-binding term sheet (the “Term Sheet”) to the Company, which outlined the terms under which the Investors would make an investment in the Company (the “Transaction”). The proposed terms and conditions submitted to the Company’s management and board of directors included the following:

 

   

The purchase by the Investors of $35 million of Common Stock of the Company at $3.85 per share.

 

   

$20 million of the proceeds of the Transaction would be used for repayment of the Company’s term loan and $15 million would be used for general corporate purposes and liquidity. As a condition to closing the Transaction, the Company would have to obtain a waiver to the mandatory prepayment upon equity issuance requirement under its existing credit agreement.

 

   

The Investors would receive four seats out of seven on the Company’s board of directors. The Company would provide registration rights to the Investors after a mutually agreed upon lock-up period with blackout periods to be negotiated.

 

   

The Company’s board of directors would agree to recommend that the Company’s shareholders vote in favor of the Transaction. The Transaction would be conditioned on the receipt of approval by the Company’s shareholders and any required approvals from Nasdaq with respect to the listing of the shares.

 

   

The expected signing date of the Transaction would be August 31, 2020, with a closing date predicated on the shareholder approval process.

Because of the non-binding nature of the Term Sheet, the Investors have no obligation to complete the Transaction. Moreover, the Company has not accepted the terms and conditions of the Term Sheet and has no obligation to Complete the Transaction.

The foregoing summary of the Term Sheet does not purport to be complete and are subject to, and qualified in its entirety by, the full text of such Term Sheet, which is filed herewith as Exhibit 2, and is incorporated herein by reference in its entirety.

As part of their ongoing evaluation of their investment in the securities covered by this Schedule 13D and investment alternatives, the Reporting Persons may consider such matters in the future, and subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, the Reporting Persons may hold discussions with management or the board of directors of the Company, other holders of securities of the Company or other third parties regarding such matters. The Reporting Persons retain the right to change their investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by them, in any manner permitted by law.

 

Item 5.

Interest in Securities of the Issuer.

There are no changes to the Item 5 information previously filed.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Except as referenced herein, there are no changes to the Item 6 information previously filed.

 

Item 7.

Material to be Filed as Exhibits.

 

Exhibit

  

Description

1    Joint Filing Agreement, date as of August 3, 2020 by and between the Reporting Persons, attached hereto.
2    Non-binding Term Sheet, dated as of July 31, 2020, attached hereto.


SIGNATURES

After reasonable inquiry and to the best of his or her knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: August 3, 2020      

/s/ Brian Pratt

      Brian Pratt
     

/s/ Barbara Pratt

      Barbara Pratt


EXHIBITS TO BE FILED WITH THIS SCHEDULE 13D

 

Exhibit

  

Description

1    Joint Filing Agreement, date as of August 3, 2020 by and between the Reporting Persons, attached hereto.
2    Non-binding Term Sheet, dated as of July 31, 2020, attached hereto.

 

EX-99.1

EXHIBIT 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of Common Stock, $0.0001 par value per share, of Limbach Holdings, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 3rd day of August, 2020.

 

/s/ Brian Pratt

Brian Pratt

/s/ Barbara Pratt

Barbara Pratt

 

EX-99.2

EXHIBIT 2

Non-Binding Term Sheet


LOGO      LOGO                 
    

Brian Pratt

5950 Berkshire Lane

Suite 800

Dallas, TX 75225

July 31, 2020

Charlie Bacon

Limbach Holdings, Inc.

5102 W. Laurel Street, Suite 800

Tampa, Florida 33607

cc: Board of Directors

Dear Charles:

We are writing to you today to propose a material investment by Blue Wolf Capital Fund IV, L.P. (“Blue Wolf” or the “Fund”) and Brian Pratt in Limbach Holdings, Inc. (“Limbach” or the “Company”) and are pleased to present this term sheet (the “Term Sheet”) to the board of directors outlining the terms under which we would make an investment in the common stock of Limbach (the “Transaction”).

We believe the proposed Transaction is in the best interests of the Company and its existing shareholders, as it will provide capital to significantly de-lever the balance sheet and provide liquidity to navigate through existing operational challenges. The proposed investment in common stock aligns Blue Wolf and Brian Pratt’s interests with existing shareholders and provides the capital required for the Company to begin to execute on its well-developed M&A strategy, further diversifying the business model and providing an unobstructed path for appreciation of the common shares. Furthermore, we believe the collective experience of Blue Wolf and Brian Pratt investing in, operating and growing specialty contractors uniquely positions us to support management’s objectives of improving project selection and execution and aggressively pursuing a transition to owner-direct and service work in an effort to accelerate growth and profitability in the years ahead.

We look forward to working with you and the board of directors to agree on terms that will best position the Company to execute its strategic plan and create value for shareholders.

 

Best Regards,           

 

    

 

     
Bennet Grill      Brian Pratt      
Principal           
Blue Wolf Capital Partners LLC           


LOGO

Limbach Holdings, Inc. –Term Sheet for Common Equity Investment

 

Issuer    Limbach Holdings, Inc. (“the Company”)
Investors    Blue Wolf Capital Fund IV, L.P. and Brian Pratt
Investment Size    $35 million
Type of Security    Common stock
Issuance Price    $3.85 per share
Use of Proceeds    $20 million for repayment of the Company’s term loan and $15 million for general corporate purposes and liquidity. As a condition to closing, the Company must obtain a waiver to the mandatory prepayment upon equity issuance requirement under its existing credit agreement.
Board Representation    Four board seats out of seven
Registration Rights    Provided after a mutually agreed upon lock-up period with blackout periods to be negotiated.
Board Recommendation    The board of directors will agree to recommend that the Company’s shareholders vote in favor of the transaction.
Approvals    The transaction will be conditioned on the receipt of approval by the Company’s shareholders and any required approvals from Nasdaq with respect to the listing of the shares.
Timing    Signing would be targeted for August 31, 2020, with a closing date predicated on the shareholder approval process.